疟疾寄生虫血症对单剂与两剂HPV疫苗接种抗体应答的影响:坦桑尼亚女孩DoRIS减剂量免疫原性试验结果
该研究基于坦桑尼亚9-14岁HIV阴性女学生(n=930)的DoRIS减剂量免疫原性试验,分析接种时疟疾寄生虫血症对HPV疫苗抗体应答的影响。单剂组未见疟疾与抗体几何平均浓度或亲和力指数差异;两剂Cervarix®组M36 HPV16 GMC比值0.74(95%CI 0.55-0.99)、AI比值0.95(95%CI 0.91-0.99),两剂Gardasil®9组M36 HPV18 GMC比值0.58(95%CI 0.37-0.92)、AI比值0.93(95%CI 0.87-0.99),均见于有疟疾者较低。结论认为两剂组效应多较小、可能无临床意义,单剂组结果令人放心但需更大样本验证。
要点
- 单剂HPV疫苗组中,接种时有无疟疾寄生虫血症者抗体GMC与AI无差异证据。
- 两剂Cervarix®组M36 HPV16 GMC比值0.74(95%CI 0.55-0.99),有疟疾者较低。
- 两剂Gardasil®9组M36 HPV18 GMC比值0.58(95%CI 0.37-0.92),首剂时有疟疾者较低。
核心结论
- 两剂HPV疫苗组中观察到疟疾对部分抗体应答有小幅影响,但多无临床意义。
- 单剂组结果令人放心,但需更大规模人群进一步验证。
- 中度或重度感染及更高寄生虫负荷的潜在影响仍不明确。
研究设计与样本
- 基于DoRIS减剂量免疫原性试验的疟疾子研究,纳入930名9-14岁HIV阴性坦桑尼亚女学生。
- 受试者随机接受一剂、两剂或三剂Cervarix®或Gardasil®9(每组155人),随访至M36。
- 单剂与两剂组进入长期延伸研究并纳入本疟疾子研究。
- 每次接种访视采集干血斑,以定量聚合酶链反应检测疟疾寄生虫血症。
- 在M12、24、36和60检测HPV16/18抗体应答。
主要发现
- 单剂组中,接种时有疟疾与无疟疾者的抗体GMC或AI无差异证据。
- 两剂Cervarix®组中,任一接种访视有疟疾者M36 HPV16 GMC比值0.74(95%CI 0.55-0.99)、AI比值0.95(95%CI 0.91-0.99)。
- 两剂Gardasil®9组中,首剂接种时有疟疾者较无疟疾者M36 HPV18 GMC比值0.58(95%CI 0.37-0.92)、AI比值0.93(95%CI 0.87-0.99)。
- 上述趋势在M60仍可观察到。
关键数值与推荐
- 两剂Cervarix®组M36 HPV16 GMC比值=0.74(95%CI 0.55-0.99),AI比值=0.95(95%CI 0.91-0.99)。
- 两剂Gardasil®9组M36 HPV18 GMC比值=0.58(95%CI 0.37-0.92),AI比值=0.93(95%CI 0.87-0.99)。
临床怎么用
- 在疟疾流行区推进HPV疫苗接种时,单剂方案抗体应答未见受接种时疟疾寄生虫血症影响。
- 两剂方案中疟疾对部分抗体指标有小幅降低,但幅度多较小、可能无临床意义,可作为接种策略参考。
局限性
- 中度或重度疟疾感染及更高寄生虫负荷的影响尚不明确。
- 单剂组结果需在更大规模人群中进一步评估确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human papillomavirus (HPV) vaccination is a key component of the World Health Organization's global strategy for cervical cancer elimination. The effect of malaria, a known immunomodulator, on HPV vaccine immunogenicity is poorly understood. This study assessed the effect of malaria parasitaemia at the time of vaccination on HPV vaccine immune responses among participants in a dose-reduction immunogenicity trial (DoRIS). METHODS AND FINDINGS: 930 HIV-negative Tanzanian schoolgirls aged 9-14 years were randomised to receive one, two or three doses of Cervarix® or Gardasil®9 (155 per arm) and followed to month (M)36. One-dose and two-dose arms participants were enrolled in a long-term extension and are included in this malaria sub-study. Dried blood spots at each vaccination visit were tested for malaria parasitaemia by quantitative polymerase chain reaction. HPV16/18 antibody responses were measured at M12, 24, 36 and 60. In the one-dose arms, there was no evidence of a difference in antibody geometric mean concentrations (GMC) or avidity index (AI) between participants with and without malaria at the time of vaccination. In the two-dose Cervarix® arm, M36 HPV16 antibody GMCs and AI results were lower in participants with malaria at either vaccination visit (HPV16 GMC ratio = 0.74, 95%CI = 0.55-0.99; AI ratio = 0.95, 95%CI = 0.91-0.99). In the two-dose Gardasil®9 arm, M36 HPV18 antibody GMCs and AI results were lower in participants with malaria at the first vaccine dose than those without malaria (HPV18 GMC ratio = 0.58, 95%CI = 0.37-0.92; AI ratio = 0.93, 95%CI = 0.87-0.99). These trends were also observed at M60. CONCLUSIONS: Whilst some effect of malaria on antibody responses was observed in the two-dose arms, these were mostly small in magnitude and unlikely to have clinical significance. Single-dose arms results are reassuring but further evaluations in larger populations would be valuable to confirm the findings. The potential for an effect of moderate or severe infection with greater parasite burden remains unclear. (NCT02834637).
引用
- Whitworth HS, Beshir KB, Baisley KJ, et al. Effect of malaria parasitaemia on antibody responses to single-dose and two-dose HPV vaccination: results from the DoRIS dose-reduction immunogenicity trial in Tanzanian girls. Vaccine. 2026. PMID: 42378813. doi:10.1016/j.vaccine.2026.128889
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。